Last updated on November 2019

An Open-Label Trial Of Oral Selegiline 5 Or 10 Mg And Tadalafil 2.5 Mg Co-Administration To Male Patients With Parkinson's Disease And Moderate Erectile Dysfunction.


Brief description of study

An Open-Label Trial Of Oral Selegiline 5 Or 10 Mg And Tadalafil 2.5 Mg Co-Administration To Male Patients With Parkinson's Disease And Moderate Erectile Dysfunction.

Detailed Study Description

The purpose of this study is to see if selegiline and tadalafil (generic for Cialis®) results in an improvement in Erectile dysfunction (ED) in male patients with Parkinson's disease (PD) and moderate ED. Male PD patients who have an incomplete response to tadalafil alone will be given both medications to see if the addition of selegiline improves ED symptoms more than tadalafil alone. It is common practice for a medical doctor to prescribe these two drugs to a patient like you. However, there have been no studies conducted to examine the effects of these medications when taken together.

Selegiline is normally prescribed for PD patients that are taking carbidopa/levodopa who are not receiving complete benefit from carbidopa/levodopa.

Tadalafil is normally prescribed to men who have erectile dysfunction and/or benign prostatic hyperplasia (BPH).

Clinical Study Identifier: TX139189

Find a site near you

Start Over
Sorry. There are no research sites conducting this study in the radius provided. ( View all Sites )
If you would like to be informed of other studies that may be of interest to you, you may sign up for CenterWatch.com's Patient Notification Service.